Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas

27 Sept 2018

Abstract excerpt

Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating activity-based proteomic profiling and drug screens, polo-like kinase-1 (PLK1) was identified as an essential regulator of the MYC-dependent kinome in DHL. Notably, PLK1 was expressed at high levels in DHL, correlated with MYC expression, and connoted poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30260324
DOI: 10.1172/jci122533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomasPMID 30260324Read ↗

Single-cell analysis characterizes PLK1 as a catalyst of an immunosuppressive tumor microenvironment in LUADSemantic proximity Read ↗

MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approachesSemantic proximity Read ↗

MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphomaSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy SpecimensSemantic proximity Read ↗

Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classificationSemantic proximity Read ↗

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read ↗

Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesisSemantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.